Prediction of the severity of colorectal lesion by fecal hemoglobin concentration observed during previous test in the French screening program.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
21 Aug 2021
Historique:
received: 12 02 2021
revised: 03 05 2021
accepted: 20 07 2021
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 11 9 2021
Statut: ppublish

Résumé

The rate of positive tests using fecal immunochemical test (FIT) does not decrease with subsequent campaigns, but the positive predictive value of advanced neoplasia significantly decreases in subsequent campaign after a first negative test. A relationship between the fecal hemoglobin concentration (Fhb) and the opportunity to detect a colorectal cancer in subsequent campaign has been shown. To predict the severity of colorectal lesions based on Fhb measured during previous colorectal cancer screening campaign. This etiological study included 293750 patients aged 50-74, living in Auvergne-Rhône-Alpes (France). These patients completed at least two FIT [test The test The study showed that higher Fhb

Sections du résumé

BACKGROUND BACKGROUND
The rate of positive tests using fecal immunochemical test (FIT) does not decrease with subsequent campaigns, but the positive predictive value of advanced neoplasia significantly decreases in subsequent campaign after a first negative test. A relationship between the fecal hemoglobin concentration (Fhb) and the opportunity to detect a colorectal cancer in subsequent campaign has been shown.
AIM OBJECTIVE
To predict the severity of colorectal lesions based on Fhb measured during previous colorectal cancer screening campaign.
METHODS METHODS
This etiological study included 293750 patients aged 50-74, living in Auvergne-Rhône-Alpes (France). These patients completed at least two FIT [test
RESULTS RESULTS
The test
CONCLUSION CONCLUSIONS
The study showed that higher Fhb

Identifiants

pubmed: 34497450
doi: 10.3748/wjg.v27.i31.5272
pmc: PMC8384754
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5272-5287

Informations de copyright

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Références

J Gastroenterol Hepatol. 2019 Jan;34(1):103-112
pubmed: 29968937
Am J Gastroenterol. 2018 Dec;113(12):1891-1899
pubmed: 30337703
Gastroenterology. 2012 Mar;142(3):497-504
pubmed: 22108194
Gastroenterol Clin North Am. 2018 Sep;47(3):515-536
pubmed: 30115435
World J Gastroenterol. 2019 May 21;25(19):2383-2401
pubmed: 31148909
JGH Open. 2020 Apr 16;4(5):898-902
pubmed: 33102761
World J Gastroenterol. 2016 Feb 14;22(6):1925-34
pubmed: 26877600
J Clin Pathol. 2013 May;66(5):415-9
pubmed: 23418340
Am J Gastroenterol. 2017 Jan;112(1):37-53
pubmed: 27753435
Eur J Cancer Prev. 2017 Sep;26(5):365-367
pubmed: 27433880
World J Gastroenterol. 2013 Dec 7;19(45):8366-72
pubmed: 24363529
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
World J Gastrointest Oncol. 2019 Sep 15;11(9):729-740
pubmed: 31558977
AJR Am J Roentgenol. 2009 Jul;193(1):40-6
pubmed: 19542393
Gastrointest Endosc. 2019 Mar;89(3):518-522
pubmed: 30142350
Ann Intern Med. 2009 Feb 3;150(3):162-9
pubmed: 19189905
Int J Cancer. 2019 Jul 1;145(1):110-121
pubmed: 30585621
Gastroenterology. 2017 Nov;153(5):1251-1259.e2
pubmed: 28760383
Lancet Oncol. 2013 Jul;14(8):711-20
pubmed: 23746988
Dig Liver Dis. 2014 Jan;46(1):82-6
pubmed: 24011791
Br J Cancer. 2011 May 24;104(11):1779-85
pubmed: 21559011
Ann Intern Med. 2014 Feb 4;160(3):171
pubmed: 24658694
N Engl J Med. 2012 Feb 23;366(8):697-706
pubmed: 22356323
Cancer Epidemiol. 2013 Dec;37(6):959-67
pubmed: 24035240
Gut. 2013 Mar;62(3):409-15
pubmed: 22387523
World J Gastroenterol. 2014 Jan 28;20(4):1038-47
pubmed: 24574776

Auteurs

Christian Balamou (C)

Site de l'Ain, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Bourg-en-Bresse 01000, France. cbalamou@yahoo.fr.

Akoï Koïvogui (A)

Site de Seine-Saint-Denis, Centre Régional de Coordination des Dépistages des Cancers en Ile-de-France, Bondy 93146, France.

Christelle M Rodrigue (CM)

Site de l'Ain, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Bourg-en-Bresse 01000, France.

Aurélie Clerc (A)

Sites Savoie & Haute Savoie, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Chambéry 73000, France.

Claire Piccotti (C)

Site de Drôme Ardèche, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Valence 26000, France.

Anne Deloraine (A)

Sites Savoie & Haute Savoie, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Chambéry 73000, France.

Catherine Exbrayat (C)

Site Isère & Drôme-Ardèche, Centre Régional de Coordination des Dépistages des Cancers en Auvergne-Rhône-Alpes, Meylan 38240, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH